Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2025
Xiangxue Pharmaceutical fined over false annual report records and fund occupation disclosure
The company announced the penalty decision: Xiangxue failed to recognize losses from demolished villas as required, resulting in false records in its 2019 annual report, and failed to disclose non-operating occupation of funds by related parties as required. The company was ordered to rectify, warned and fined 6 million yuan; the actual controller and other responsible persons were separately punished. Status: the company announced it had received the administrative penalty decision. Entity involved: Guangzhou Xiangxue Pharmaceutical Co., Ltd.
2025
Xiangxue Pharmaceutical fined and publicly censured over false annual report records and concealed fund occupation
Xiangxue Pharmaceutical made false records in its annual report and concealed related-party fund occupation; in 2025 it was fined 6 million yuan by the Guangdong bureau of the China Securities Regulatory Commission, and actual controller Wang Yonghui was fined 10 million yuan. In 2026, it was publicly censured by the Shenzhen Stock Exchange for sharply revising its earnings forecast from a loss of about 600-900 million yuan to 1.2-1.5 billion yuan and failing to timely disclose delisting risk. Fine, public censure, *ST.